Skip to main content
. 2014 Oct 2;141(2):547–559. doi: 10.1093/toxsci/kfu150

FIG. 10.

FIG. 10.

Neuregulin-1β (NRG) attenuates and trastuzumab (TZM) potentiates doxorubicin (Dox)-induced cardiomyocyte injury. (A) Representative screenshots of spontaneous beating cells taken from wells before or after exposure to Dox (1μM) or vehicle (0.1% DMSO) following pretreatment with NRG (100 ng/ml) or TZM (1μM) for 24 h. Horizontal scale bar: 3 s; vertical scale bar: 0.05 arbitrary units. (B) Real-time monitoring of cellular impedance for cells exposed to 0.3 or 1-μM Dox after pre-treatment with NRG (100 ng/ml) or TZM (1μM) for 24 h. Readings for each well were normalized to the baseline level prior to Dox application (marked by the arrow). For clarity, not all treatment groups are shown. Cellular impedance and intracellular ATP measured after 40-h exposure to Dox are plotted in (C) and (D). Data point for each concentration is the average of 9–12 wells from four to five separate experiments. RLU: relative light units; *p < 0.05 compared with Dox; #p < 0.05 compared with NRG 1μM + Dox.